The idea that cancer treatment might work better at certain times of day has circulated for decades but has rarely faced rigorous clinical testing.
Now, a randomized trial of 210 people with advanced lung cancer affirms that timing really matters, researchers report February 2 in Nature Medicine.
The study is the first controlled trial to examine whether the timing of immune therapy affects patient outcomes, offering the strongest evidence yet that circadian biology — the body’s internal clock — can shape how well cutting-edge cancer drugs mobilize the immune system against tumors.
#newsletter-helper svg { width: auto; fill: #f1563e; } #newsletter-helper { display: flex; border-top: